SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Three-Year Real-World LEQEMBI Data Presented at CTAD 2026

The LEQEMBI LEADER study analysis includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe Alzheimer’s disease, subcutaneous maintenance experience and sex-based outcomes.

4523BIIB

Related stories